STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
Clinical trials for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE trials appear
Sign up with your email to follow new studies for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ancient heat therapy tested for Life-Threatening transplant complication
Disease control Recruiting nowThis study tests whether moxibustion, a traditional Chinese medicine technique that involves burning dried mugwort near the skin, can help people with a severe complication of stem cell transplants called graft-versus-host disease (GVHD) that does not respond to steroids. The tri…
Matched conditions: STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Cord blood cells join forces with drug to fight transplant complication
Disease control Recruiting nowThis early study tests whether adding special cells from donated umbilical cord blood (called mesenchymal stromal cells) to the drug ruxolitinib can help control severe graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a serious complication where donor…
Matched conditions: STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for chinese patients with severe transplant complication: ruxolitinib trial launches
Disease control Recruiting nowThis study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patie…
Matched conditions: STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC